MedTrace Logo

Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19

NCT04361318 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-04-24

No results posted yet for this study

Summary

In December 2019, a new infectious respiratory disease emerged in Wuhan, Hubei province, China. An initial cluster of infections was linked to Huanan seafood market, potentially due to animal contact. Subsequently, human-to-human transmission occurred and the disease, now termed coronavirus disease 19 (COVID-19) rapidly spread within China and all over the world. A novel coronavirus, SARS-coronavirus 2 (SARS-CoV-2), which is closely related to SARS-CoV, was detected in patients and is believed to be the etiologic agent of the new lung disease. The causative agent of the current COVID-19 pandemic, SARS-CoV-2, is a single stranded positive sense RNA virus that is closely related to severe acute respiratory syndrome coronavirus (SARS-CoV).

Conditions

Interventions

COMBINATION_PRODUCT

Hydroxychloroquine plus Nitazoxanide

Both hydroxychloroquine \& nitazoxanide will be administered orally to participating patients

OTHER

Standard care

Oxygen administered via ventilator. In addition, antipyretic "paracetamol" may be added if necessary

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Kamal Okasha, MD, PhD · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-31
Primary Completion
2020-10-31
Completion
2020-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04361318 on ClinicalTrials.gov